Dogwood Therapeutics (NASDAQ:DWTX) Issues Quarterly Earnings Results

Dogwood Therapeutics (NASDAQ:DWTX) posted its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07, Zacks reports.

Dogwood Therapeutics Trading Up 4.6%

DWTX stock traded up $0.09 during trading on Thursday, reaching $1.95. 57,773 shares of the stock were exchanged, compared to its average volume of 80,034. The business has a 50 day moving average price of $2.14 and a 200-day moving average price of $3.68. Dogwood Therapeutics has a 1 year low of $1.28 and a 1 year high of $9.50. The firm has a market capitalization of $64.96 million, a price-to-earnings ratio of -0.10 and a beta of 1.68.

Analyst Ratings Changes

DWTX has been the topic of several research reports. Weiss Ratings downgraded Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent SEC filing. 9.05% of the stock is owned by institutional investors.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.